Anna V. Serebryakova
Anna V. Serebryakova has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Evgeniya Yu. Zyablitskaya
V.I. Vernadsky Crimean Federal University
3 shared publications - Kazim A. Aliev
V.I. Vernadsky Crimean Federal University
3 shared publications - Leya E. Sorokina
V.I. Vernadsky Crimean Federal University, Ministry of Science and Higher Education of the Russian Federation, Simferopol
3 shared publications Е. Ю. Зяблицкая
Медицинская академия им. С.И. Георгиевского ФГАОУ ВО «Крымский федеральный университет им. В.И. Вернадского
2 shared publications- A. I. Balakchina
S.I. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University
1 shared publication - A. V. Kubyshkin
S.I. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University
1 shared publication
Latest Publications
- 30 December 2025
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 33 (4) , 499-508
VEGF-dependent angiogenesis in therapeutic pathomorphosis of breast cancer
INTRODUCTION: The involvement of angiogenic factors in the tumor progression and invasion processes, in escape from immunological surveillance and alterations in the signal sensitivity implicates the perspectiveness of investigating VEGF-dependent angiogenesis in the context of therapeutic regression of breast cancer (BC). AIM: To study the immunohistochemical features of angiogenesis markers: vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang2) and its receptor tyrosine kinase (Tie2), depending on the degree of breast carcinoma regression with the underlying neoadjuvant chemotherapy (NACT). METHODS: The study included 65 patients with verified locally advanced breast cancer and 10 patients with proliferative fibrocystic disease. Breast cancer patients underwent NACT according to the following regimen: 5-fluorouracil 500 mg/m2, adriamycin (=doxorubicin) 50 mg/m2, cyclophosphamide (FAC) 500 mg/m2. At the screening stage, a core needle biopsy of the breast tumor was performed, and an examination of the surgical material upon completion of NACT. The key marker for breast cancer, the human epidermal growth factor receptor-2 (Her2/neu), and angiogenesis markers (VEGF-A, Ang2, Tie2) were assessed using the immunohistochemical method, and morphological regression of the tumor was determined using the residual cancer burden (RCB) system. RESULTS: The most common type of breast carcinoma is invasive ductal breast carcinoma, luminal A, Her2/neu-negative subtype. Immunohistochemical characteristics of breast carcinoma angiogenesis are independent of the morphological and surrogate molecular subtype of tumor. Parameters of angiogenesis activity (VEGF-A, Ang2, Tie2) are maximally expressed in patients with the proliferative fibrocystic disease and BC before the start of NACT. NACT produces a weak suppressive effect on the parameters of angiogenesis activity irrespective of tumor type. CONCLUSION: Objectification of the obtained results and clarification of the specific angiogenesis features in BC patients undergoing neoadjuvant chemotherapy requires further investigation of this matter using additional molecular genetic methods. We believe it would be appropriate to conduct experimental studies of the effects of cytostatic agents in various regimens (including ultra-low doses), as well as to conduct additional studies on the role of integrins and Notch receptors.
- 30 December 2025
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 33 (4) , 499-508
VEGF-dependent angiogenesis in therapeutic pathomorphosis of breast cancer
INTRODUCTION: The involvement of angiogenic factors in the tumor progression and invasion processes, in escape from immunological surveillance and alterations in the signal sensitivity implicates the perspectiveness of investigating VEGF-dependent angiogenesis in the context of therapeutic regression of breast cancer (BC). AIM: To study the immunohistochemical features of angiogenesis markers: vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang2) and its receptor tyrosine kinase (Tie2), depending on the degree of breast carcinoma regression with the underlying neoadjuvant chemotherapy (NACT). METHODS: The study included 65 patients with verified locally advanced breast cancer and 10 patients with proliferative fibrocystic disease. Breast cancer patients underwent NACT according to the following regimen: 5-fluorouracil 500 mg/m2, adriamycin (=doxorubicin) 50 mg/m2, cyclophosphamide (FAC) 500 mg/m2. At the screening stage, a core needle biopsy of the breast tumor was performed, and an examination of the surgical material upon completion of NACT. The key marker for breast cancer, the human epidermal growth factor receptor-2 (Her2/neu), and angiogenesis markers (VEGF-A, Ang2, Tie2) were assessed using the immunohistochemical method, and morphological regression of the tumor was determined using the residual cancer burden (RCB) system. RESULTS: The most common type of breast carcinoma is invasive ductal breast carcinoma, luminal A, Her2/neu-negative subtype. Immunohistochemical characteristics of breast carcinoma angiogenesis are independent of the morphological and surrogate molecular subtype of tumor. Parameters of angiogenesis activity (VEGF-A, Ang2, Tie2) are maximally expressed in patients with the proliferative fibrocystic disease and BC before the start of NACT. NACT produces a weak suppressive effect on the parameters of angiogenesis activity irrespective of tumor type. CONCLUSION: Objectification of the obtained results and clarification of the specific angiogenesis features in BC patients undergoing neoadjuvant chemotherapy requires further investigation of this matter using additional molecular genetic methods. We believe it would be appropriate to conduct experimental studies of the effects of cytostatic agents in various regimens (including ultra-low doses), as well as to conduct additional studies on the role of integrins and Notch receptors.
- Open Access
- 14 December 2023
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 10 (4) , 8-20
Cellular microenvironment as an object of targeted therapy for malignant neoplasms
The dynamic relationships between tumor cells and their microenvironment are of crucial importance in the development and progression of the malignant process. Given the multifunctional potential of heterogeneous populations surrounding a tumor, targeting components of the microenvironment has long been regarded as a promising strategy in modern anticancer therapy. This review discusses the role of the components of the cellular microenvironment in carcinogenesis, analyzes in detail the main ways and mechanisms of action on the main cell populations, which are of the greatest interest in the context of the development of innovative anticancer therapy.
- 14 December 2023
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 10 (4) , 8-20
Open AccessCellular microenvironment as an object of targeted therapy for malignant neoplasms
The dynamic relationships between tumor cells and their microenvironment are of crucial importance in the development and progression of the malignant process. Given the multifunctional potential of heterogeneous populations surrounding a tumor, targeting components of the microenvironment has long been regarded as a promising strategy in modern anticancer therapy. This review discusses the role of the components of the cellular microenvironment in carcinogenesis, analyzes in detail the main ways and mechanisms of action on the main cell populations, which are of the greatest interest in the context of the development of innovative anticancer therapy.
- Open Access
- 19 July 2023
- Published by Publishing House OKI in Pharmacogenetics and Pharmacogenomics
- No. 1,p. 33-45
Molecular genetic features of hereditary forms of breast cancer (systematic review)
The interest in the problem of hereditary forms of breast cancer is due not only to the increase in the number of patients, but also to the existing features in relation to the phenotypic characteristics of these tumors, course features, and sensitivity to various therapy options. Unfortunately, the data of clinical trials that exist to date do not provide a complete picture of the course of various forms of hereditary breast cancer, sensitivity to therapeutic agents, adequate examination volumes and preventive measures. In this regard, there is a need to conduct prospective randomized trials to optimize treatment, screening and prevention programs. The rapid development of technologies in the field of molecular biology has made it possible to identify about 20 genes, the presence of mutations in which causes an increased risk of developing breast cancer. The aim of this review was to summarize the available data on the role of structural rearrangements of genes of varying degrees of penetrance associated with hereditary predisposition to breast cancer. The mechanism of hereditary breast cancer forms development is associated with rearrangements in DNA repair genes of varying degrees of penetrance. The identification of these mutations is of strategic importance for early diagnosis and the transition from an empirical to a targeted personalized approach in the treatment of various types of cancer. Understanding the pathogenesis of the disease at the molecular level makes it possible to make a breakthrough in the field of pharmacological innovations in order to create new selective classes of drugs in effective targeted therapy.
- 19 July 2023
- Published by Publishing House OKI in Pharmacogenetics and Pharmacogenomics
- No. 1,p. 33-45
Open AccessMolecular genetic features of hereditary forms of breast cancer (systematic review)
The interest in the problem of hereditary forms of breast cancer is due not only to the increase in the number of patients, but also to the existing features in relation to the phenotypic characteristics of these tumors, course features, and sensitivity to various therapy options. Unfortunately, the data of clinical trials that exist to date do not provide a complete picture of the course of various forms of hereditary breast cancer, sensitivity to therapeutic agents, adequate examination volumes and preventive measures. In this regard, there is a need to conduct prospective randomized trials to optimize treatment, screening and prevention programs. The rapid development of technologies in the field of molecular biology has made it possible to identify about 20 genes, the presence of mutations in which causes an increased risk of developing breast cancer. The aim of this review was to summarize the available data on the role of structural rearrangements of genes of varying degrees of penetrance associated with hereditary predisposition to breast cancer. The mechanism of hereditary breast cancer forms development is associated with rearrangements in DNA repair genes of varying degrees of penetrance. The identification of these mutations is of strategic importance for early diagnosis and the transition from an empirical to a targeted personalized approach in the treatment of various types of cancer. Understanding the pathogenesis of the disease at the molecular level makes it possible to make a breakthrough in the field of pharmacological innovations in order to create new selective classes of drugs in effective targeted therapy.